Table 1.
Clinicopathological characteristics of the 796 patients with RCC.
| TFE3-positiveRCC | TFE3-negative RCC | P | P* | |||
|---|---|---|---|---|---|---|
| Total(n=91) | Xp11.2 translocation RCC (n=31) | Non-Xp11.2 translocation RCC (n=60) | (n=705) | |||
| Median age (range, years) | 54 (19–77) | 43 (24-74) | 59 (19-77) | 58 (23-90) | <0.001 | <0.001 |
| Gender | 0.048 | 0.149 | ||||
| Male | 54 | 14 | 40 | 472 | ||
| Female | 37 | 17 | 20 | 233 | ||
| Median tumor size (range, cm) | 4.5 (1.1-16.5) | 4.4 (2.2-16.5) | 4.5 (1.1-12) | 3.9 (0.7-19.5) | 0.235 | 0.056 |
| Tumor location | 0.242 | 0.555 | ||||
| Left | 51 | 20 | 31 | 372 | ||
| Right | 40 | 11 | 29 | 333 | ||
| Lymph node metastasis | 0.084 | <0.001 | ||||
| YES | 10 | 6 | 4 | 9 | ||
| NO | 81 | 25 | 56 | 696 | ||
| Distant metastasis | 0.405 | <0.001 | ||||
| Yes | 6 | 3 | 3 | 6 | ||
| No | 85 | 28 | 57 | 699 | ||
| WHO/ISUP grade | NA | <0.001 | ||||
| 1+2 | 24 | NA | 24 | 518 | ||
| 3+4 | 33 | NA | 33 | 153 | ||
| AJCC stage | 0.406 | 0.002 | ||||
| I+II | 72 | 23 | 49 | 634 | ||
| III+IV | 19 | 8 | 11 | 71 | ||
| Histopathological subtype of RCC | NA | NA | ||||
| Clear cell | 45 | 0 | 46 | 626 | ||
| Papillary | 12 | 0 | 11 | 45 | ||
| Chromophobe | 3 | 0 | 3 | 15 | ||
| Xp11.2 translocation | 31 | 31 | 0 | 0 | ||
| Others | 0 | 0 | 0 | 19 | ||
RCC, renal cell carcinoma; NA, not available; P, TFE3-positive Xp11.2 translocation vs non-Xp11.2 translocation RCC cases; P*, TFE3-positive vs TFE3-negative RCC cases; Bold values indicate P<0.05.